abstract Both Erythropoietin (EPO) and bone marrow stromal cells (BMSCs) have been shown to improve outcome after stroke. EPO may improve outcome after stroke through its actions on blood progenitor cells, angiogenesis, or direct action in the CNS. BMSCs may improve outcome after stroke by regeneration, altering plasticity of viable cells, or prevention of cell death. Sorting out these potential modes of actions for EPO and BMSCs has been difficult using in vivo models of stroke. This study investigated neuroprotection afforded by EPO, BMSCs and the combination of these modalities in mouse hippocampal slice cultures after oxygen glucose deprivation (OGD). Significant neuroprotection was observed following post-injury treatment of slice cultures with BMSCs and neuroprotection was augmented by treating BMSCs with EPO. EPO alone did not protect neurons from OGD when given after injury, but was effective when given prior to OGD. The failure of EPO to protect when given after injury did not appear to result from its inability to activate EPO signaling pathways involving phosphorylation of Akt. This study supports the implication that BMSCs may rescue dying neurons after ischemia by providing trophic support. The data also show that EPO's actions as a neuroprotective agent following stroke may be mediated by its actions on BMSCs. 
Introduction
In recent years, blood derived factors have been targeted as potential therapeutic agents for treatment of stroke. Among these are erythropoietin and progenitor cells from bone marrow. Erythropoietin (EPO) is a 34kDa glycoprotein produced by the kidney and CNS tissue [1] in response to hypoxic stresses such as high altitude, cardiac arrest, emphysema, asthma and stroke. Clinically, EPO has been used for more than a decade to treat anemia, bone marrow decomposition in association with HIV, chemotherapy related depletion of erythrocytes subsequent to treatment of cancer, chronic renal failure and was examined in a multi-center clinical trial for stroke [2, 3] .
EPO exerts a direct effect on erythrocytic precursor cells in endogenous bone marrow resulting in erythropoiesis, angiogenesis, a decrease in apoptosis, and increased delivery of oxygen to depleted tissue as a result of hypoxic stress [2, 4, 5] . In addition to the erythrocytic precursors, EPO receptor expression and the effects of EPO are observed in other cell types including neural cells [6] .
The downstream mechanisms of the EPO initiated response after ischemia are well defined [7, 8] . EPO exerts its influence primarily through the recruitment and differentiation of bone marrow precursor cells to become hematocytes. Bone marrow-derived cells, including bone marrow stromal cells (BMSCs) are also confirmed contributors of CNS neuroprotection after ischemia in animals [9, 10] . Exogenous cultured BMSCs express the EPO receptor (EPOr) and EPO is known to increase the viability of the BMSC cultures [5] .
It has been proposed that BMSCs increase cell survival after injury by providing increased trophic support to the injured CNS [11] .
EPO increases oxygenation of the tissue by erythropoeisis and enhances proliferation and survival of BMSCs, potentially influencing a relatively hostile environment to become a conducive milieu for survival [4, 12] .
Although studies of treatment with EPO or
BMSCs independently results in significant neuroprotection in various injury models, the analysis of the combination of these therapies after injury is novel. The aim of this research was to directly compare neuroprotection provided by EPO, BMSCs, and the combination of BMSCs with EPO using the organotypic slice culture model of in-vitro ischemia.
Materials and Methods
All procedures involving animals were conducted with approval of the University of Miami Animal Care and Use Committee according to established federal guidelines.
Hippocampal Organotypic Slice Cultures
Organotypic slice cultures of the hippocampus were prepared according to the methods described previously [13] with modifications to meet the current experimental paradigm. C57Bl mice pups (7-9 days old) were anesthetized by intraperitoneal injections of ketamine (.5 mg/pup). The pups were decapitated and 
Treatment in-vitro with Erythropoietin
Erythropoietin-α (EPO-α) was delivered in culture medium either 24 hrs before OGD or immediately after OGD for 24 hours in the following concentrations: 0.1U/ml, 1 U/ml, 10 U/ml, and 100 U/ml. Data are described here for treatment with 1.0 U/ml as no differences 
Bone Marrow Stromal Cell Cultures
BMSCs were isolated from individual GFP {C57BL/6-TgN(ACTbEGFP)1Osb Jackson Laboratory} mice as described by Song and Sanchez-Ramos [14] . GPF mice were used to 
Statistical Analysis of Data
All fluorescent intensities are expressed as mean ±SEM percentage of the hippocampal area of interest given the described condition.
Statistical significance was assessed using ANOVA.
Differences were considered statistically significant at P<0.05. Post hoc analysis to determine significant difference between groups was obtained using Tukey's Post Hoc and Dunnett Two Sided Test.
Statistical significance was accepted at P<0.05.
results

neuroprotective effect of bMSCs coupled with Epo-a in-vitro
In the following experiments, we compared neuroprotection by BMSCs and EPO using hippocampal slice cultures and OGD. We compared neuroprotection provided by BMSCs alone, BMSCs in the presence of EPO, and EPO alone given both before and after ODG. Average cell death in control slice cultures after OGD was 96.9 ± 0.6 % (mean ± SEM) in subfield CA1, 90.7 ± 3.8% in subfield CA3, and 75.9 ± 6.1% in the dentate gyrus (Figure 2 ). Greater neuronal death in subfield CA1 than in CA3
or dentate gyrus was observed consistently throughout this study and confirmed that selective neuronal vulnerability to OGD was a feature of organotypic slice cultures. with EPO before and after OGD. These data are summarized in Figure 5 . While there were no differences in total Akt among groups we found that OGD resulted in increased levels of the 66 Kd EPO receptor subunit and increased levels of phospho-Akt. There were no differences between EPO pre-treatment and post-treatment groups that could explain the lack of neuroprotection by EPO when given after injury. In fact, levels of EPO receptor and phospho-Akt were higher in post-treated slices, but likely due to the effects of OGD rather than enhanced activation by EPO. brain trauma [18, 19] and spinal cord injury [20] [21] [22] [23] Using a model of chemically induced apoptosis in neurons, Isele et al [29] found that BMSCs exposed to medium derived from injured neurons provided better neuroprotection than BMSCs cultured in the absence on damaged cells.
discussion
Like BMSC therapy, EPO has been shown to improve outcome after stroke [30, 31] . The mechanisms by which EPO improves outcome is largely unknown but may involve improved brain oxygenation through hematopoeisis [31] or angiogenesis [4, 31] , or its direct actions on neurons and glia [6] . Both neurons and glia express receptors for EPO [7] , and activate downstream signaling pathways in response to EPO exposure [32] . EPO exerts its function through the activation of the downstream cascade commencing with the EPOr signaling through the IP3 pathway, subsequently activating AKT, resulting in the expression of many anti-apoptotic, anti-oxidant, and antiinflammatory factors [32] . Akt is one of the downstream regulators of anti-apoptotic factors and transcription factors associated with neuroprotection in-vivo after ischemia by EPO implementation or endogenous upregulation [4, 8, [32] [33] [34] . Exposing the hippocampal slice culture preparations to EPO prior to injury influences the tissue to initiate this pathway in the absence of injury resulting in increased cell survival [7] .
Previously published data suggested that invivo EPO mediated neuroprotection is a result of paracrine production of EPO by astrocytes and upregulation of EPOr on both astrocytes and neurons of the CNS [7, 35] . Treatment with EPO prior to ischemia (pre-conditioning) protects neurons both in vitro [36] and in vivo [30, 33] , possibly by activating these pathways.
We confirmed here that pretreatment of organotypic slice cultures with EPO provided neuroprotection when the slices subsequently were deprived of oxygen and glucose.
In contrast, our finding that treatment with EPO after OGD was ineffective is at odds with numerous studies that show improved outcome when EPO was given after ischemia in vivo [2, 4, 6] . We speculated that perhaps the failure of EPO to provide protection when given after injury might result from down 
